Zymeworks Inc. (ZYME)
12.87
-0.18 (-1.38%)
At close: Mar 25, 2025, 3:59 PM
-1.38% (1D)
| Bid | 12.19 |
| Market Cap | 895.11M |
| Revenue (ttm) | 70M |
| Net Income (ttm) | -112.55M |
| EPS (ttm) | -1.62 |
| PE Ratio (ttm) | -7.94 |
| Forward PE | -8.46 |
| Analyst | Buy |
| Ask | 13.3 |
| Volume | 393,169 |
| Avg. Volume (20D) | 522,276 |
| Open | 13.19 |
| Previous Close | 13.05 |
| Day's Range | 12.67 - 13.15 |
| 52-Week Range | 7.97 - 17.70 |
| Beta | 1.13 |
About ZYME
Zymeworks Inc., a clinical-stage biopharmaceutical company, discovers, develops, and commercializes biotherapeutics for the treatment of cancer. The company's lead product candidates include zanidatamab, a novel bispecific antibody that is in Phase 1 and Phase 2 clinical trials for the treatment of biliary tract, gastroesophageal adenocarcinomas, breast, and colorectal cancer; and ZW49, a biparatopic anti-human epidermal growth factor receptor 2 ...
Industry Biotechnology
Sector Healthcare
IPO Date Apr 28, 2017
Employees 280
Stock Exchange NYSE
Ticker Symbol ZYME
Website https://www.zymeworks.com
Analyst Forecast
According to 6 analyst ratings, the average rating for ZYME stock is "Buy." The 12-month stock price forecast is $18.5, which is an increase of 43.80% from the latest price.
Stock ForecastsNext Earnings Release
Zymeworks Inc. is scheduled to release its earnings on May 1, 2025,
during market hours.
Analysts project revenue of ... Unlock content with Pro Subscription
Analysts project revenue of ... Unlock content with Pro Subscription
2 weeks ago
-7.97%
Zymeworks shares are trading lower after the compa...
Unlock content with
Pro Subscription
3 months ago
+9.46%
Zymeworks shares are trading higher after JP Morgan upgraded the stock from Neutral to Overweight and announced a price target of $18.
